CSBR · Champions Oncology, Inc. · Executive Compensation
Market Cap
$70.98M
Shares
13.92M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2026
| Executive | Role | Total |
|---|---|---|
| Robert Brainin | Chief Executive Officer | $3,567,022 |
| David Miller | Chief Financial Officer | $388,464 |
| Ronnie Morris | Chief Executive Officer | $233,333 |
| Brady Davis | President | — |
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ronnie Morris | Chief Executive Officer | $600,000 |
| David Miller | Chief Financial Officer | $310,777 |
| Brady Davis | President | $177,083 |
| Robert Brainin | Chief Executive Officer | — |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brady Davis | President | $1,346,210 |
| Ronnie Morris | Chief Executive Officer | $400,000 |
| David Miller | Chief Financial Officer | $260,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ronnie Morris | Chief Executive Officer | $600,000 |
| David Miller | Chief Financial Officer | $294,303 |
| Brady Davis | President | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ronnie Morris | Chief Executive Officer | $800,000 |
| David Miller | Chief Financial Officer | $321,538 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ronnie Morris | Chief Executive Officer | $775,000 |
| David Miller | Chief Financial Officer | $311,681 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ronnie Morris | Chief Executive Officer | $1,343,653 |
| David Miller | Chief Financial Officer | $372,915 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David Miller | Chief Financial Officer | $275,000 |
| Ronnie Morris | Chief Executive Officer | $146,281 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Brian Alexander | director of the Company | Appointed | 2026-03-30 |
| Dr. Philip Breitfeld | member of the Board | Resigned | 2026-03-30 |